Enhanced Glaucoma Treatment Systems using Ultrashort Laser Pulses

The inventive concept presents a series of direct improvements and enhancements to the original patent, focusing on the development of more efficient, safer, and more effective systems and methods for treating glaucoma using ultrashort laser pulses.

The original patent describes methods for treating glaucoma using visible and infrared ultrashort laser pulses. However, the existing approach has limitations, such as the need for precise targeting, potential tissue damage, and limited visualization of Schlemm's canal. The new inventive concept addresses these limitations by introducing advanced systems and methods that enhance the original patent's capabilities.

The new claims introduce several key innovations, including the use of a gonioscopic control system for precise targeting, an optical coupling system for precise targeting of outflow obstructing tissues, a feedback mechanism to monitor and adjust laser pulse energy in real-time, and a pressure gradient control system to enhance visualization of Schlemm's canal. These advancements enable more efficient and safer treatment of glaucoma, reducing the risk of tissue damage and improving patient outcomes.

The new claims demonstrate novelty and inventive step over the original patent by introducing specific improvements and enhancements that address the limitations of the existing approach. The use of advanced systems and methods, such as the gonioscopic control system and the feedback mechanism, provide a non-obvious solution to the problem of precise targeting and tissue damage.

Alternative embodiments of the inventive concept could include the use of different laser pulse ranges, alternative delivery systems, or modified gonioscopic control systems. These variations could enable further enhancements to the original patent, expanding the scope of the inventive concept and providing additional solutions for treating glaucoma.

The enhanced glaucoma treatment systems and methods described in the new claims have significant commercial potential, particularly in the ophthalmic industry. The inventive concept could be marketed as a premium solution for glaucoma treatment, offering improved safety, efficiency, and patient outcomes. The target market could include ophthalmologists, medical device manufacturers, and healthcare providers seeking advanced solutions for glaucoma treatment.